H.C. Wainwright Flag KRRO-121 as Independent Value Driver for Korro Bio, Inc. (KRRO)

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Korro Bio, Inc. is next on our list of best biotech stocks.

TheFly reported on January 29 that H.C. Wainwright upgraded KRRO from Neutral to Buy with a $20 price target. The firm highlighted KRRO-121 as a second, independently risk-mitigated asset and described it as a “call option” that is separate from the company’s earlier KRRO-110 program. H.C. Wainwright highlighted the independent potential of KRRO-121 by pointing out that KRRO’s shares are trading close to zero enterprise value.

Similarly, on the same day, Chardan Capital also upgraded Korro Bio, Inc. (NASDAQ:KRRO) from Neutral to Buy with a $15 price target following the company’s analyst day. The upgrade reflected the firm’s view that KRRO has “turned the page,” supported by strong preclinical data for KRRO-121.

Korro Bio, Inc. (NASDAQ:KRRO) is a biopharmaceutical company developing precision genetic medicines by editing RNA to treat rare and prevalent diseases. Using its proprietary OPERA platform, KRRO advances RNA‑editing therapies, including clinical and preclinical programs.

While we acknowledge the potential of KRRO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.